Clindamycin palmitate hydrochloride: Difference between revisions
Gerald Chi (talk | contribs) (Created page with "__NOTOC__") |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Clindamycin palmitate hydrochloride}} | |||
{{CMG}}; {{AE}} {{AK}} | |||
'''''For patient information, click <u>[[Clindamycin palmitate hydrochloride (patient information)|here]]</u>'''''. | |||
==Overview== | |||
Clindamycin (rINN) (IPA: [klɪndəˈmaɪsən]) is a lincosamide antibiotic used in the treatment of infections caused by susceptible microorganisms. Clindamycin is a semisynthetic antibiotic derived from lincomycin by 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the lincomycin. Clindamycin is marketed under various trade names including Dalacin (Pfizer), Cleocin (Pfizer), and in a foam as Evoclin (Connetics) and Duac(Stiefel). | |||
==Category== | |||
[[Lincosamides]] | |||
==US Brand Names== | |||
CLEOCIN HYDROCHLORIDE® | |||
==FDA Package Insert== | |||
''' [[Clindamycin palmitate hydrochloride description|Description]]''' | |||
'''| [[Clindamycin palmitate hydrochloride clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Clindamycin palmitate hydrochloride microbiology|Microbiology]]''' | |||
'''| [[Clindamycin palmitate hydrochloride indications and usage|Indications and Usage]]''' | |||
'''| [[Clindamycin palmitate hydrochloride contraindications|Contraindications]]''' | |||
'''| [[Clindamycin palmitate hydrochloride warnings|Warnings]]''' | |||
'''| [[Clindamycin palmitate hydrochloride precautions|Precautions]]''' | |||
'''| [[Clindamycin palmitate hydrochloride adverse reactions|Adverse Reactions]]''' | |||
'''| [[Clindamycin palmitate hydrochloride overdosage|Overdosage]]''' | |||
'''| [[Clindamycin palmitate hydrochloride dosage and administration|Dosage and Administration]]''' | |||
'''| [[Clindamycin palmitate hydrochloride how supplied|How Supplied]]''' | |||
'''| [[Clindamycin palmitate hydrochloride labels and packages|Labels and Packages]]''' | |||
==References== | |||
{{Reflist|2}} | |||
http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50162s082,50441s045,50639s013lbl.pdf | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]]__NOTOC__ | |||
Latest revision as of 17:34, 9 January 2014
| Clindamycin palmitate hydrochloride |
|---|
| CLINDAMYCIN PALMITATE HYDROCHLORIDE® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Overdosage |
| Dosage and Administration |
| How Supplied |
| Labels and Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
For patient information, click here.
Overview
Clindamycin (rINN) (IPA: [klɪndəˈmaɪsən]) is a lincosamide antibiotic used in the treatment of infections caused by susceptible microorganisms. Clindamycin is a semisynthetic antibiotic derived from lincomycin by 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the lincomycin. Clindamycin is marketed under various trade names including Dalacin (Pfizer), Cleocin (Pfizer), and in a foam as Evoclin (Connetics) and Duac(Stiefel).
Category
US Brand Names
CLEOCIN HYDROCHLORIDE®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50162s082,50441s045,50639s013lbl.pdf